SCHEMBL3265586

SCHEMBL3265586

CNC(=O)COC(=O)NCCC1CCN(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.54
POLB P06746 4/20 0.48
LMNA P02545 5/20 0.47
MAPK1 P28482 2/20 0.47
RAB9A P51151 1/20 0.47
NOTUM Q6P988 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
USP2 O75604 1/20 0.45
HTT P42858 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
HSD17B10 Q99714 1/20 0.44
ACACB O00763 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240152 0.88 CHRM4 (0.56) CHRM4POLBLMNAMAPK1RAB9A
SCHEMBL2979849 0.86 CHRM4 (0.56) CHRM4CHRM2CHRM1
SCHEMBL3265530 0.83 POLB (0.46) POLBLMNAMAPK1RAB9ANOTUM
SCHEMBL3269874 0.83 POLB (0.47) POLBLMNAMAPK1RAB9AMEN1
SCHEMBL1727477 0.82 CHRM4 (0.66) CHRM4POLBLMNAMAPK1RAB9A
SCHEMBL5234744 0.79 ALDH1A1 (0.67) POLBLMNAMAPK1RAB9AMEN1
SCHEMBL2976065 0.79 CHRM4 (0.56) CHRM4CHRM2CHRM1
SCHEMBL3265668 0.78 CHRM4 (0.51) CHRM4CHRM2
SCHEMBL3268986 0.78 HSD11B1 (0.41) CHRM4ACACB
SCHEMBL29489154 0.77 TGM2 (0.44) CHRM4ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CHRM4 243/4885POLB 1541/4885LMNA 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.